UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clonal evolution in myeloma: a narrow road to remission

Haematologica (Roma), 2019-07, Vol.104 (7), p.1292-1293

Miething, Cornelius C

2019

Volltextzugriff (PDF)

Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)

Annals of oncology, 2018-10, Vol.29, p.viii646-viii646

2018

Volltextzugriff (PDF)

Grb10 is involved in BCR-ABL-positive leukemia in mice

Leukemia, 2015-04, Vol.29 (4), p.858-868

2015

Volltextzugriff (PDF)

High expression of bcl-2 mRNA as a determinant of poor prognosis acute myeloid leukemia

Annals of oncology, 1998-02, Vol.9 (2), p.159-165

1998

Volltextzugriff (PDF)

The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia

Leukemia, 2002-05, Vol.16 (5), p.846-854

2002

Volltextzugriff (PDF)

Senescence of Activated Stellate Cells Limits Liver Fibrosis

Cell, 2008-08, Vol.134 (4), p.657-667

2008

Volltextzugriff (PDF)

Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma – a case report and review of the literature

Journal of stomatology, oral and maxillofacial surgery, 2020-11, Vol.121 (5), p.599-603

2020

Volltextzugriff (PDF)

IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA‐INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL

Hematological oncology, 2017-06, Vol.35 (S2), p.163-163

2017

Volltextzugriff (PDF)

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib

Leukemia, 2006-04, Vol.20 (4), p.650-657

2006

Volltextzugriff (PDF)

Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin d2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27

Leukemia, 2002-03, Vol.16 (3), p.327-334

2002

Volltextzugriff (PDF)

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells

Oncogene, 2008-07, Vol.27 (31), p.4380-4384

2008

Volltextzugriff (PDF)

1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial

Annals of oncology, 2020-09, Vol.31, p.S1085-S1085

2020

Volltextzugriff (PDF)

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

Blood, 2000-09, Vol.96 (5), p.1933-1939

2000

Volltextzugriff (PDF)

1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma

Annals of oncology, 2022-09, Vol.33, p.S1295

2022

Volltextzugriff (PDF)

Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model

Cancer cell, 2009-10, Vol.16 (4), p.324-335

2009

Volltextzugriff (PDF)

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

Blood, 2005-06, Vol.105 (12), p.4792-4799

2005

Volltextzugriff (PDF)

1824PLenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Genomic organization and regulation of the human interleukin-18 gene

Scandinavian journal of immunology, 2000-12, Vol.52 (6), p.525-530

2000

Volltextzugriff (PDF)

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)

Blood, 2003-09, Vol.102 (6), p.2236-2239

2003

Volltextzugriff (PDF)

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor

Blood, 2003-07, Vol.102 (2), p.646-651

2003

Volltextzugriff (PDF)

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo

Leukemia, 2003-09, Vol.17 (9), p.1695-1699

2003

Volltextzugriff (PDF)

RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model

Blood, 2013-04, Vol.121 (17), p.3402-3412

2013

Volltextzugriff (PDF)

Nucleophosmin–anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway

Blood, 2000-12, Vol.96 (13), p.4319-4327

2000

Volltextzugriff (PDF)

Effects of imatinib on bone marrow engraftment in syngeneic mice

Leukemia, 2002-09, Vol.16 (9), p.1584-1588

2002

Volltextzugriff (PDF)

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

Blood, 1997-08, Vol.90 (3), p.1217-1225

1997

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(66)
Reviews
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(40)
Humans
(27)
Animals
(26)
Mice
(22)
Biological And Medical Sciences
(18)
Hematology
(18)
Medical Sciences
(14)
Oncology
(14)
Hematologic And Hematopoietic Diseases
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Female
(10)
Biochemistry & Molecular Biology
(9)
Cell Biology
(9)
Imatinib Mesylate
(9)
Piperazines - Pharmacology
(9)
Benzamides
(8)
Cell Line
(8)
Mutation
(8)
Pyrimidines - Pharmacology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clonal evolution in myeloma: a narrow road to remission

Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)

Grb10 is involved in BCR-ABL-positive leukemia in mice

High expression of bcl-2 mRNA as a determinant of poor prognosis acute myeloid leukemia

The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia

Senescence of Activated Stellate Cells Limits Liver Fibrosis

Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma – a case report and review of the literature

IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA‐INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib

Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin d2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells

1915P The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines

1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma

Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

1824PLenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)

Genomic organization and regulation of the human interleukin-18 gene

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo

RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model

Nucleophosmin–anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway

Effects of imatinib on bone marrow engraftment in syngeneic mice

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

Suchergebnisse filtern